AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1...
Hence then, the article about alebund pharmaceuticals announces collaboration and license agreement with r1 therapeutics for ap306 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 )
Also on site :
- Chelsea vs Luton Town: Blues Target Strong EFL Cup Start
- 1975 Frank-N-Furter, Secret Weapon Built by Tim Curry From David Bowie’s Ziggy Stardust DNA, Earned the Greatest Response Bowie Ever Gave
- Nordstrom Rack’s ‘Stylish’ Sorel Mary Jane Loafers Are ‘Instantly Comfortable’ Out of the Box, and 50% Off